Department of Pharmacology and Toxicology, Virginia Commonwealth University, Richmond, VA, 23298, USA.
Psychopharmacology (Berl). 2019 Mar;236(3):1057-1066. doi: 10.1007/s00213-018-5029-y. Epub 2018 Sep 19.
Synthetic cathinones constitute a class of abused drugs that can act at dopamine, norepinephrine, and serotonin transporters (DAT, NET, and SERT, respectively). Intracranial self-stimulation (ICSS) is a preclinical procedure that can be used to evaluate abuse potential of drugs, and prior studies have indicated that abuse-related ICSS effects of monoamine-transporter substrates, including some synthetic cathinones, are positively correlated with drug selectivity for DAT vs. SERT. Abuse potential of drugs can also be influenced by regimens of repeated drug exposure, but the role of repeated exposure on abuse-related ICSS effects of synthetic cathinones has not been examined.
This study used ICSS to evaluate effects of repeated treatment with the DAT>SERT substrate methcathinone, the DAT<SERT substrate fenfluramine, and the DAT≈SERT substrate mephedrone.
Male Sprague-Dawley rats were trained in a frequency-rate ICSS procedure, and different groups were used to evaluate effects of methcathinone, mephedrone, and fenfluramine before, during, and after regimens of repeated treatment with the designated drug.
Before repeated treatment, methcathinone produced dose-dependent and abuse-related ICSS facilitation, fenfluramine produced dose-dependent ICSS depression, and mephedrone produced mixed effects that included both facilitation and depression. Chronic treatment produced no change in effects of methcathinone, but complete tolerance to effects of fenfluramine. For mephedrone, chronic treatment produced partial tolerance to ICSS depression and enhanced expression of ICSS facilitation.
Repeated exposure to mixed-action DAT≈SERT substrates such as mephedrone can result in increased abuse potential due to sustained expression of DAT-mediated abuse-related effects and tolerance to SERT-mediated abuse-limiting effects.
合成卡西酮属于一类被滥用的药物,可分别作用于多巴胺、去甲肾上腺素和血清素转运体(DAT、NET 和 SERT)。颅内自我刺激(ICSS)是一种可用于评估药物滥用潜力的临床前程序,先前的研究表明,包括一些合成卡西酮在内的单胺转运体底物的与滥用相关的 ICSS 效应与药物对 DAT 与 SERT 的选择性呈正相关。药物的滥用潜力也会受到重复药物暴露方案的影响,但重复暴露对合成卡西酮与滥用相关的 ICSS 效应的作用尚未得到检验。
本研究使用 ICSS 评估 DAT>SERT 底物甲卡西酮、DAT<SERT 底物芬氟拉明和 DAT≈SERT 底物 4-甲基甲卡西酮的重复治疗的影响。
雄性 Sprague-Dawley 大鼠在频率速率 ICSS 程序中进行训练,不同的组别用于评估甲卡西酮、4-甲基甲卡西酮和芬氟拉明在重复治疗方案之前、期间和之后对 ICSS 的影响。
在重复治疗之前,甲卡西酮产生了剂量依赖性和与滥用相关的 ICSS 促进作用,芬氟拉明产生了剂量依赖性的 ICSS 抑制作用,而 4-甲基甲卡西酮则产生了包括促进和抑制作用的混合效应。慢性治疗对甲卡西酮的作用没有改变,但对芬氟拉明的作用完全耐受。对于 4-甲基甲卡西酮,慢性治疗产生了对 ICSS 抑制作用的部分耐受,并增强了 ICSS 促进作用的表达。
重复暴露于混合作用的 DAT≈SERT 底物,如 4-甲基甲卡西酮,可能会由于 DAT 介导的与滥用相关的效应的持续表达和对 SERT 介导的限制滥用的效应的耐受而导致滥用潜力增加。